Former FDA Commissioner Dr. Scott Gottlieb speaking at the Healthy Returns conference in New York City on May 21, 2019.
Astrid Stawiarz | CNBC
Scott Gottlieb, who stepped down as Food and Drug Administration Commissioner in April, will join Pfizer‘s board of directors, the company announced Thursday.
Gottlieb resigned from the FDA this spring after nearly two years at the helm. During his tenure, Gottlieb advanced a number of prescription drug policies, including to push the FDA to speed up generic drug approvals and use its powers to encourage wider use of biosimilars, or copycat versions of complex and often costly biologic drugs.
Biosimilar manufacturers, including Pfizer, have complained about roadblocks stalling biosimilars from becoming widely used. Having Gottlieb to advise the company could help Pfizer, one of the largest biopharmaceutical companies, navigate the landscape.
CEO Albert Bourla, who succeeded Ian Read on January 1, shuffled the company’s senior management team last…
